A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
NCT04025879
Active Not Recruiting
The main purpose of the study is to examine if periadjuvant (neoadjuvant, then adjuvant) immunotherapy will prolong event free survival in participants with early stage non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: Local Institution - 0104, Tampa, Florida +107 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
NCT00542451
Completed
The purpose of this study is to find out what effect the postoperative combination of therapies: trastuzumab (herceptin) and paclitaxel (taxol) will have on breast cancer recurrence. A combination of trastuzuamb and chemotherapy has been used in women with node positive and high risk node negative disease. This tests utilizes a well tolerated regimen of weekly paclitaxel and trastuzumab in women with T1, node negative tumors that are HER2 positive. We would like to determine how effective this d... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/24/2024
Locations: University of California-San Francisco, San Francisco, California +19 locations
Conditions: Breast Cancer, Carcinoma of the Breast
Register for Updates
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
NCT03493854
Completed
This is a global Phase III, two-arm, open-label, multicenter, randomized study to investigate the pharmacokinetics, efficacy, and safety of the fixed-dose combination (FDC) of pertuzumab and trastuzumab for subcutaneous (SC) administration in combination with chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in the neoadjuvant/adjuvant setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Maryland Oncology Hematology, Rockville, Maryland +106 locations
Conditions: Early Breast Cancer
Register for Updates
Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy
NCT03393741
Terminated
Eligible subjects will be assigned to study treatment arms by their treating oncologist, rather than by the study. The drug, dose, and schedule of administration will be determined by the treating physician per NCCN guidelines for standard of care chemotherapy regimens for recurrent or metastatic breast cancer. Study treatment arms include: Taxane (nab-paclitaxel or paclitaxel), Eribulin, Vinorelbine, Ixabepilone, or the control arm (non-microtubule targeted chemotherapies such as doxorubicin, c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Conditions: Breast Cancer, Breast Neoplasms
Register for Updates
A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
NCT03530397
Active Not Recruiting
The purpose of this study is to evaluate MEDI5752 and carboplatin and pemetrexed or paclitaxel or nab-paclitaxel in adult subjects with advanced solid tumors, when administered as a single agent or combined with chemotherapy.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/21/2024
Locations: Research Site, Detroit, Michigan +39 locations
Conditions: Selected Advanced Solid Tumors
Register for Updates
Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma
NCT03077685
Completed
Open-label, dose-escalating, Phase IIa trial of NanoPac® to treat subjects with locally advanced pancreatic adenocarcinoma via direct intratumoral injection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California +3 locations
Conditions: Locally Advanced Pancreatic Adenocarcinoma
Register for Updates
Study of SRF617 in Patients With Advanced Solid Tumors
NCT04336098
Completed
A Phase 1, first-in-human, monotherapy and combination dose escalation and expansion study of SRF617.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: City of Hope, Duarte, California +9 locations
Conditions: Advanced Solid Tumor
Register for Updates
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT02488967
Active Not Recruiting
This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whethe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: Southern Cancer Center PC-Mobile, Mobile, Alabama +1295 locations
Conditions: Breast Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Register for Updates
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
NCT03307785
Active Not Recruiting
Part A: To test the safety and tolerability of combination therapy with Niraparib and TSR-042 and to establish a safe dose that will be used in a Phase 2 study. Part B: To test the safety and tolerability of combination therapy with Carboplatin-Paclitaxel and TSR-042 and to establish a safe dose that will be used in a Phase 2 study. Part C: To test the safety and tolerability of combination therapy with Niraparib, TSR-042 and Bevacizumab and to establish a safe dose that will be used in a Phas... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2024
Locations: GSK Investigational Site, Scottsdale, Arizona +7 locations
Conditions: Neoplasms, Metastatic Cancer, Advanced Cancer, Solid Tumor, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Stage IIIB, Non Small Cell Lung Cancer
Register for Updates
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
NCT03367871
Terminated
The investigators propose to evaluate the efficacy of the combination of standard chemotherapy with bevacizumab with Pembrolizumab in women with recurrent, persistent, or metastatic cervical cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/24/2024
Locations: University of Miami, Miami, Florida
Conditions: Cervical Cancer
Register for Updates
A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies
NCT03719326
Completed
This is a Phase 1/1b, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of etrumadenant (AB928) in combination with pegylated liposomal doxorubicin (PLD) with or without IPI-549 in participants with advanced metastatic triple-negative breast cancer (TNBC) or ovarian cancer, and etrumadenant in combination with nanoparticle albumin-bound-paclitaxel (NP) in participants with advanced metasta... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/23/2024
Locations: Scottsdale Healthcare Hospitals dba Honor Health Research Institute, Scottsdale, Arizona +26 locations
Conditions: TNBC - Triple-Negative Breast Cancer, Ovarian Cancer
Register for Updates
QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
NCT03387098
Terminated
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with pancreatic cancer who have progressed on or after previous SoC chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: Chan Soon-Shiong Institute for Medicine, El Segundo, California
Conditions: Pancreatic Cancer
Register for Updates